FDA Quality Management System Regulation (QMSR) QMSR-Transition: Transition from prior QSR + 2 February 2026 application + FDA inspection approach

TRANSITION PATH from prior QSR to QMSR: the FDA Final Rule (89 FR 7496) provides a 2-year implementation period - the QMSR applies from 2 FEBRUARY 2026 + manufacturers must fully implement the harmonised QMSR by that date. KEY TRANSITION ACTIVITIES: (a) GAP ANALYSIS between existing QSR-compliant QMS + the QMSR (incorporating ISO 13485:2016) - identify procedures that must be updated; (b) DOCUMENTATION UPDATE - update Quality Manual + procedures + work instructions to reference ISO 13485:2016 Section 4-8 + the §820.15 clarifications + §820.35 record controls + §820.45 labelling; (c) TRAINING - retrain QMS personnel on harmonised terminology + ISO 13485:2016 Section structure + FDA clarifications; (d) ISO 13485:2016 CERTIFICATION CONSIDERATION - manufacturers who do not already hold ISO 13485:2016 certification should consider obtaining it from an FDA-accredited Notified Body or Conformity Assessment Body to demonstrate QMSR compliance + facilitate dual EU + US validation; (e) FDA INSPECTION APPROACH POST-2026 - FDA will inspect against QMSR + may issue 483 observations + warning letters + consent decrees for non-compliance; the FDA has clarified that the transition does NOT require re-certification - existing QSR-compliant systems are evaluated against QMSR during routine inspections; (f) MDSAP (Medical Device Single Audit Program) - the MDSAP audit programme already audits against ISO 13485:2016 + provides a pathway for parallel FDA + Australia TGA + Brazil ANVISA + Canada Health Canada + Japan PMDA inspections.